BHL to start its commercial production at Plot no. N 92, MIDC, Tarapur

Bajaj Healthcare Limited (BHL) a leading manufacturer of APIs, Intermediates and Formulations, has announced to start commercial production of Nimesulide API at Plot No. N-92, MIDC, Tarapur. "Nimesulide API" used for relief from pain and prevention of fever. BHL has received approval from FDA Maharashtra (India), to manufacture and market "Nimesulide API" as approved medication for pain relief and prevention of fever in India and will commence its commercial production from tomorrow onwards.

In FY21, the Company has acquired stressed assets from the Saraswat Cooperative Bank under SARFAESI Act, 2002, which comprises of three manufacturing units and one engineering unit at MIDC, Tarapur and having installed capacity of 111 MT per month. BHL has received an approval to start its commercial production in one of the manufacturing unit acquired under SARFAESI Act, 2002 at Plot No. N-92, MIDC, Tarapur.

Commenting on the "commencement of commercial production at Plot no. N 92, MIDC, Tarapur ", Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said "We are pleased to start of commercial production at one of the manufacturing unit acquired under SARFAESI Act, 2002 from Saraswat Bank i.e. at Plot no. N 92, MIDC, Tarapur. This manufacturing unit has Installed Capacity of 40 MT/ p.m. BHL will start commercial production of Nimesulide API from tomorrow onwards at Plot no. N 92, MIDC, Tarapur.

FDA Maharashtra (India), has granted permission to manufacture and sales the "Nimesulide API" in the domestic as well as in overseas market.

Shares of Bajaj Healthcare Limited was last trading in BSE at Rs. 879.9 as compared to the previous close of Rs. 869.9. The total number of shares traded during the day was 15340 in over 1106 trades.

The stock hit an intraday high of Rs. 885 and intraday low of 844. The net turnover during the day was Rs. 13483614.

Source : Equity Bulls

Keywords